Last reviewed · How we verify
Hib Vaccine Group
Hib vaccine stimulates the immune system to produce antibodies against Haemophilus influenzae type b (Hib) bacteria, preventing infection.
Hib vaccine stimulates the immune system to produce antibodies against Haemophilus influenzae type b (Hib) bacteria, preventing infection. Used for Prevention of invasive Haemophilus influenzae type b disease in infants and children.
At a glance
| Generic name | Hib Vaccine Group |
|---|---|
| Also known as | Haemophilus Influenzae Type b Conjugate Vaccine, ActHIB® |
| Sponsor | Beijing Minhai Biotechnology Co., Ltd |
| Drug class | vaccine |
| Target | Haemophilus influenzae type b polysaccharide capsule |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
The vaccine contains components of the Hib bacterial capsule conjugated to a carrier protein, which triggers both humoral and cellular immune responses. This results in the production of protective antibodies and immunological memory, preventing invasive Hib disease including meningitis, epiglottitis, and bacteremia.
Approved indications
- Prevention of invasive Haemophilus influenzae type b disease in infants and children
Common side effects
- Local injection site reactions (pain, redness, swelling)
- Fever
- Irritability
Key clinical trials
- Left Atrial Appendage Closure With Versus Without Pulsed Field Ablation in Atrial Fibrillation Patients With Mild Symptoms and High Stroke Risk (NA)
- Perioperative Systemic Therapy for Isolated Resectable Colorectal Peritoneal Metastases (PHASE2, PHASE3)
- A Contrast Medium Sparing Strategy Using Automated CO2 Injection During PVI for Prevention of Major Adverse Kidney Events (MAKE) (PHASE3)
- A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation (PHASE2)
- Effect of an Exercise Rehabilitation Program on Symptoms in Hemodialysis (NA)
- FHD-286 With Low-Dose Weekly Decitabine/Venetoclax in Patients With Acute Myeloid Leukemia (PHASE1)
- A Phase II Trial of a Recombinant Human Anti-Rabies Virus Monoclonal Antibody (PHASE2)
- A Study Assessing the Safety, Efficacy, and Impact of GlaxoSmithKline Biologicals' RTS, S/AS01E Malaria Vaccine in Young Children Across Sub-Saharan Africa
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Hib Vaccine Group CI brief — competitive landscape report
- Hib Vaccine Group updates RSS · CI watch RSS
- Beijing Minhai Biotechnology Co., Ltd portfolio CI